Cantargia receives patent approval from the USPTO for IL1RAP in acute lymphoblastic leukemia
The United States Patent and Trademark Office (“USPTO”) has formally granted Cantargia AB’s (“Cantargia”) patent application for use of IL1RAP as target molecule for antibody therapy of acute lymphoblastic leukemia (“ALL”). The approval follows the Notice of Allowance that was issued and communicated in June 2016.The approved patent with number US 9,458,237 will be published October 4, 2016 and provides protection until 2030 and covers Cantargia’s method of using IL1RAP as target molecule for treatment of ALL. “The US is one of the largest markets for Cantargia, so this is of course good